RiskMetrics – ISS Governance Services Recommends Stockholders Vote “FOR” BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. Merger

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cell Genesys, Inc. (NASDAQ:CEGE), today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that BioSante and Cell Genesys stockholders vote “FOR” the adoption of the merger agreement between BioSante and Cell Genesys at their upcoming respective special meeting of stockholders scheduled to be held on September 30, 2009.